Sohei Muto
Overview
Explore the profile of Sohei Muto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobayashi N, Sunaga N, Yatomi M, Wakamatsu I, Muto S, Ikota H, et al.
Thorac Cancer
. 2024 Dec;
16(2):e15512.
PMID: 39731296
Histologic transformation from non-small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver...
2.
Yatomi M, Akasaka K, Sato S, Chida M, Kanbe M, Sawada H, et al.
BMC Pulm Med
. 2024 Apr;
24(1):170.
PMID: 38589870
Background: Autoimmune pulmonary alveolar proteinosis (APAP) is a diffuse lung disease that causes abnormal accumulation of lipoproteins in the alveoli; however, its pathogenesis remains unclear. Recently, APAP cases have been...
3.
Sunaga N, Miura Y, Sakurai R, Ohshima S, Uno S, Muto S, et al.
Anticancer Drugs
. 2023 Feb;
34(4):605-608.
PMID: 36729850
Lenvatinib is a multitargeted kinase inhibitor and maintaining its dose intensity has been shown to be beneficial in patients with thyroid and hepatocellular carcinomas. However, most patients require lenvatinib interruption...
4.
Yamaguchi K, Yamaguchi A, Ito M, Wakamatsu I, Itai M, Muto S, et al.
Clin Rheumatol
. 2022 Oct;
42(2):479-488.
PMID: 36194347
Introduction: Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)-ANCA. MPO-ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These...
5.
Kanbe M, Sunaga N, Hara K, Sawada H, Wakamatsu I, Hara K, et al.
Thorac Cancer
. 2022 Oct;
13(22):3225-3228.
PMID: 36193787
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are standard therapeutic agents for non-small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R...
6.
Yamaguchi K, Fukushima Y, Yamaguchi A, Itai M, Shin Y, Uno S, et al.
Respir Med
. 2022 Jan;
193:106741.
PMID: 35091206
Background: Obesity is a major risk factor for developing various respiratory diseases. Patients with anti-aminoacyl tRNA synthetase (ARS) antibodies often have interstitial lung disease (ILD). The present study was conducted...
7.
Yamaguchi K, Nakajima T, Yamaguchi A, Itai M, Onuki Y, Shin Y, et al.
Clin Rheumatol
. 2022 Jan;
41(5):1473-1481.
PMID: 35034225
Introduction: This study aimed to assess the utility of quantitative high-resolution computed tomography (HRCT) for determining the clinical course of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease (MDA5...